Tenaya Therapeutics, Inc. Research and Development Expense
Tenaya Therapeutics, Inc. (TNYA) reported Research and Development Expense of $16.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Tenaya Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $16.60M, a 4.42% decline year-over-year.
- Tenaya Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $14.84M, a 29.57% decline year-over-year.
- Tenaya Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $14.80M, a 20.82% decline year-over-year.
- Tenaya Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $15.36M, a 24.51% decline year-over-year.
- Tenaya Therapeutics, Inc. research and development expense for fiscal 2025 was $68.61M, a 20.91% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. research and development expense for fiscal 2024 was $86.74M, a 11.52% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. research and development expense for fiscal 2023 was $98.04M, a 3.70% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. research and development expense for fiscal 2022 was $94.54M, a 73.80% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.60M 10-Q · filed 2026-08-05 | $31.45M 10-Q · filed 2026-08-05 | $46.24M derived: sum of 3 quarters · filed 2026-08-05 | $61.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.84M 10-Q · filed 2026-05-06 | $29.64M derived: sum of 2 quarters · filed 2026-05-06 | $45.00M derived: sum of 3 quarters · filed 2026-05-06 | $62.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $30.16M derived: sum of 2 quarters · filed 2026-03-11 | $47.53M derived: sum of 3 quarters · filed 2026-08-05 | $68.61M 10-K · filed 2026-03-11 |
| 2025-09-30 | $15.36M 10-Q · filed 2025-11-10 | $32.73M derived: sum of 2 quarters · filed 2026-08-05 | $53.81M 10-Q · filed 2025-11-10 | $72.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $17.37M 10-Q · filed 2026-08-05 | $38.45M 10-Q · filed 2026-08-05 | $57.13M derived: sum of 3 quarters · filed 2026-08-05 | $77.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $21.08M 10-Q · filed 2026-05-06 | $39.76M derived: sum of 2 quarters · filed 2026-05-06 | $60.11M derived: sum of 3 quarters · filed 2026-05-06 | $82.76M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $18.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $39.04M derived: sum of 2 quarters · filed 2026-03-11 | $61.69M derived: sum of 3 quarters · filed 2026-03-11 | $86.74M 10-K · filed 2026-03-11 |
| 2024-09-30 | $20.35M 10-Q · filed 2025-11-10 | $43.00M derived: sum of 2 quarters · filed 2025-11-10 | $68.05M 10-Q · filed 2025-11-10 | $90.92M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $22.65M 10-Q · filed 2025-08-06 | $47.70M 10-Q · filed 2025-08-06 | $70.57M derived: sum of 3 quarters · filed 2025-08-06 | $93.66M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $25.05M 10-Q · filed 2025-05-07 | $47.92M derived: sum of 2 quarters · filed 2025-05-07 | $71.01M derived: sum of 3 quarters · filed 2025-05-07 | $97.49M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $22.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $45.96M derived: sum of 2 quarters · filed 2025-03-10 | $72.43M derived: sum of 3 quarters · filed 2025-03-10 | $98.04M 10-K · filed 2025-03-10 |
| 2023-09-30 | $23.09M 10-Q · filed 2024-11-06 | $49.57M derived: sum of 2 quarters · filed 2024-11-06 | $75.17M 10-Q · filed 2024-11-06 | $100.92M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $26.48M 10-Q · filed 2024-08-08 | $52.08M 10-Q · filed 2024-08-08 | $77.83M derived: sum of 3 quarters · filed 2024-08-08 | $101.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.61M 10-Q · filed 2024-05-14 | $51.35M derived: sum of 2 quarters · filed 2024-05-14 | $75.11M derived: sum of 3 quarters · filed 2024-05-14 | $95.99M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $25.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $49.51M derived: sum of 2 quarters · filed 2024-03-18 | $70.38M derived: sum of 3 quarters · filed 2024-03-18 | $94.54M 10-K · filed 2024-03-18 |
| 2022-09-30 | $23.76M 10-Q · filed 2023-11-08 | $44.63M derived: sum of 2 quarters · filed 2023-11-08 | $68.79M 10-Q · filed 2023-11-08 | $89.74M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $20.88M 10-Q · filed 2023-08-09 | $45.03M 10-Q · filed 2023-08-09 | $65.98M derived: sum of 3 quarters · filed 2023-08-09 | $78.93M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $24.16M 10-Q · filed 2023-05-10 | $45.11M derived: sum of 2 quarters · filed 2023-05-10 | $58.05M derived: sum of 3 quarters · filed 2023-05-10 | $68.96M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $20.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $33.90M derived: sum of 2 quarters · filed 2023-03-08 | $44.80M derived: sum of 3 quarters · filed 2023-03-08 | $54.39M 10-K · filed 2023-03-08 |
| 2021-09-30 | $12.94M 10-Q · filed 2022-11-10 | $23.85M derived: sum of 2 quarters · filed 2022-11-10 | $33.44M 10-Q · filed 2022-11-10 | $41.80M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $10.91M 10-Q · filed 2022-08-10 | $20.50M 10-Q · filed 2022-08-10 | $28.86M derived: sum of 3 quarters · filed 2022-08-10 | $37.34M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $9.59M 10-Q · filed 2022-05-11 | $17.95M derived: sum of 2 quarters · filed 2022-05-11 | $26.43M derived: sum of 3 quarters · filed 2022-05-11 | $33.39M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $16.84M derived: sum of 2 quarters · filed 2022-03-23 | $23.80M derived: sum of 3 quarters · filed 2022-03-23 | $31.10M 10-K · filed 2022-03-23 |
| 2020-09-30 | $8.48M 10-Q · filed 2021-11-10 | $15.44M derived: sum of 2 quarters · filed 2021-11-10 | $22.73M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $6.96M 10-Q · filed 2021-09-08 | $14.26M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |